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Resistin-Like Molecule- Inhibits SGLT-1 Activity and
Enhances GLUT2-Dependent Jejunal Glucose Transport
Rim Belharbi Krimi, Philippe Letteron, Pia Chedid, Corinne Nazaret, Robert Ducroc, and
Jean-Claude Marie
OBJECTIVE—An increased expression of RELM- (resistin-like
molecule-), a gut-derived hormone, is observed in animal mod-
els of insulin resistance/obesity and intestinal inﬂammation.
Intestinal sugar absorption is modulated by dietary environment
and hormones/cytokines. The aim of this study was to investigate
the effect of RELM- on intestinal glucose absorption.
RESEARCH DESIGN AND METHODS—Oral glucose toler-
ance test was performed in mice and rats in the presence and the
absence of RELM-. The RELM- action on glucose transport in
rat jejunal sacs, everted rings, and mucosal strips was explored
as well as downstream kinases modulating SGLT-1 and GLUT2
glucose transporters.
RESULTS—Oral glucose tolerance test carried out in rodents
showed that oral administration of RELM- increased glycemia.
Studies in rat jejunal tissue indicated that mucosal RELM-
promoted absorption of glucose from the gut lumen. RELM- had
no effect on paracellular mannitol transport, suggesting a trans-
porter-mediated transcellular mechanism. In studies with jejunal
mucosa mounted in Ussing chamber, luminal RELM- inhibited
SGLT-1 activity in line with a diminished SGLT-1 abundance in
brush border membranes (BBMs). Further, the potentiating
effect of RELM- on jejunal glucose uptake was associated with
an increased abundance of GLUT2 at BBMs. The effects of
RELM- were associated with an increased amount of protein
kinase C II in BBMs and an increased phosphorylation of
AMP-activated protein kinase (AMPK).
CONCLUSIONS—The regulation of SGLT-1 and GLUT2 by
RELM- expands the role of gut hormones in short-term AMPK/
protein kinase C mediated control of energy balance. Diabetes
58:2032–2038, 2009
T
he family of proteins called RELMs (resistin-like
molecules) has been reported to be involved
with insulin resistance, diabetes, and inﬂamma-
tory processes. Resistin was initially identiﬁed as
an adipokine that inhibits insulin action and adipocyte
differentiation (1). RELM- is a protein homologous to
resistin that is localized mainly within the digestive tract
(2,3). RELM- is highly expressed in goblet cells of murine
colon and is secreted in response to bacterial colonization.
It plays an important role in host defense and innate
immunity (4,5). We have shown that RELM- may have a
direct effect on intestinal goblet cell secretion (6) and
others have shown that RELM- can also act as a hor-
mone. An acute perfusion of RELM- in rat induced a
hepatic insulin resistance (7).
Recently, a concomitant increase of serum concentra-
tion and intestinal expression of RELM- has been re-
ported in insulin-resistant models such as obese db/db
mice and high-fat–fed mice (8). The intestinal expression
of RELM- in mice is controlled by fasting and by various
nutritive elements such as glucose and saturated free fatty
acids (9). Glucose reduces the enterocyte expression of
RELM-, while insulin and tumor necrosis factor- can
upregulate its expression (9). This suggests that intestinal
RELM- may not only be associated with inﬂammation but
can also be a regulator of energy homeostasis.
Glucose, the main source of energy in humans, comes
from the digestion of carbohydrates and is absorbed in the
small intestine. Intestinal sugar absorption constantly
adapts to the dietary environment (10). One risk factor for
developing noninsulin-dependent diabetes (type 2 diabe-
tes) is the excessive consumption of diets containing high
levels of carbohydrates. An important defect in type 2
diabetes is the increased ability of intestine to absorb
monosaccharides by intestinal sugar transporters (11).
Intestinal glucose is actively transported by the Na
/
glucose cotransporter-1 (SGLT-1) and passively by GLUT2
(10). Moreover, it is also becoming increasingly evident
that the gut is not just site of nutrient absorption but is
also an active endocrine organ (12,13). A paracrine regu-
lation of hexose absorption by intestinal hormones such as
glucose-dependent insulinotropic polypeptide and proglu-
cagon-derived peptides GLP-1 and GLP-2 has been shown
(10). Indeed, certain gastro-intestinal peptides secreted at
the luminal side of intestine such as leptin, angiotensin II,
and epidermal growth factor have a mucosal effect on
hexose transport (14–17). Even though glucose is the main
regulator of its own absorption, the modulatory effect of
gut-derived molecules on intestinal sugar absorption plays
a critical role in the adaptation to dietary environment.
However, to our knowledge, nothing is known concerning
the effect of RELM- on intestinal absorption of glucose. A
local action of RELM- expressed in the jejunum is likely
even though the highest expression of RELM- is found in
colonic goblet cells (2). There is also evidence that
RELM- expression can be upregulated in rat (18) and
mice (19) goblet cells of proximal intestine. Considering
that RELM- expression is regulated by nutrients/insulin
and inﬂammatory cytokines, it seems important to explore
whether RELM- can regulate glucose jejunal absorption.
In the present study, we show that exogenous RELM-
acted as a luminal effector in enhancing glycemia during
oral glucose tolerance test (OGTT) carried out in mice and
rats. The use of rat jejunal strips mounted in Ussing
chamber indicated that RELM- could directly inhibit
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AMP-activated protein kinase (AMPK) has been shown to
downregulate SGLT-1 transport and upregulate glucose
uptake by GLUT2 (20). The in vitro and in situ experiments
performed with rat jejunal segments indicate that RELM-
increases transepithelial glucose transport by switching
the active transport into passive entry. The mechanism
involved activation of AMPK and protein kinase C (PKC)
and an insertion of GLUT2 transporters in jejunal brush
border membranes (BBMs). These data suggest that
RELM-, a gut-derived hormone, can directly modulate
intestinal glucose transport.
RESEARCH DESIGN AND METHODS
Male Wistar rats weighing 220–240 g and male C57BL/6J mice weighing 20–25
g were from Centre Elevage Janvier, Le Genest-St. Isle, France. The animals
had free access to tap water and standard food and were treated in
accordance with European Community guidelines concerning care and use of
laboratory animals.
Glucose tolerance test. Gavages of conscious rats or mice with 1 g of
glucose per kilogram of body weight were performed after a 16-h fast using a
D-glucose solution without (control) or with RELM-. The total bolus volume
for mice and rats was 0.25 ml and 1 ml, respectively, and the amount of
glucose in each bolus was adjusted for the animal weight. The recombinant
murine RELM- (18 kDa; PeproTech, Neuilly-sur-Seine, France) used was
highly puriﬁed by high-performance liquid chromatography and was endotoxin-
free. RELM-, at a ﬁnal concentration of 0.1 and 1 nmol/l, results in dose range
of 0.01–0.1 g/kg of body weight. RELM- is a stable molecule as high
amounts of the homodimer form have been detected in mice and human stools
(21). Preliminary experiments showed that the peptide given by gavage was
found in proximal small intestine after 5 min with a recovery of 70%. Before
starting the OGTT, blood samples were taken from the tail and fasting blood
glucose levels (milligram per deciliter) were determined (ACCU-CHEK; Roche
Diagnostic, Meylan, France). The bleeds were further taken at 15, 30, 60, and
120 min after oral glucose administration. These experiments were performed
at least with 6–10 individual animals.
Tissue preparation and short-circuit measurement. Rats were fasted for
16 h and were killed by pentobarbital overdose. The proximal jejunum was
dissected out and four adjacent samples were mounted in Ussing chambers as
described previously (22). The tissues were bathed with 4 ml of Krebs-Ringer
bicarbonate (KRB) solution (pH 7.4) with 10 mmol/l glucose at 37°C. In the
solution bathing the mucosal side of the tissue, glucose was replaced by
mannitol. Both solutions were gassed with 95% O2/5% CO2. Electrogenic ion
transport was monitored continuously as short-circuit current (Isc) by using
an automated voltage clamp apparatus (DVC 1000; WPI, Aston, England)
linked through a MacLab 8 to a MacIntosh computer. KRB alone (vehicle) or
containing RELM- (0.001–1 nmol/l) was added in the mucosal bath 2 min
before a glucose challenge. Carbachol (100 mmol/l) was added at the end of
each experiment as a control. Further, similar tests were performed with
RELM- incubated overnight at 4°C with a rabbit polyclonal antibody raised
against RELM-. Results were expressed as the intensity of the Isc (A/cm
2)
or as the percentage of the peak Isc obtained after glucose challenge
(measured after 3 min) over basal Isc (measured just before the addition of
glucose).
Transmural transport of hexoses. The experiments were performed using
jejunal sacs from adult Wistar rats. Animals were fasted for 16 h and were
killed by pentobarbital overdose. The proximal jejunum was dissected out and
rinsed in cold saline solution. Jejunal loops (4 cm long) were prepared and 0.5
ml of KRB solution without (control) or with 1 nmol/l RELM- was inserted
inside the jejunal lumen. The jejunal loops were incubated for 15 min in
oxygenized KRB at 37°C and conditions were maintained during hexose
transport assay. The corresponding jejunal loops were ﬁlled with 1 ml of KRB
solution without (control) or with 1 nmol/l RELM- and containing 0.02
Ci/ml of the isotopic tracer D-[1-
14C] glucose (49.5 mCi/mmol) and glucose to
obtain a ﬁnal concentration of 10, 30, and 100 mmol/l. Similarly, we studied the
paracellular transport with 30 mmol/l mannitol and the isotopic tracer
D-[1-
14C] mannitol (59 mCi/mmol) at 0.2 Ci/ml. All the jejunal loops were
incubated in 10 ml of KRB solution during the indicated time. The radioactivity
was measured in the collected samples of serosal KRB solution and used to
calculate glucose or mannitol transport as picomoles per milligram of jejunal
protein. Five independent experiments were performed and signiﬁcance is
expressed as *P  0.05,**P  0.01.
Western blot analysis. Rats were anesthetized by pentobarbital and lapa-
rotomized for in situ experiments. Three jejunal segments (5 cm long) were
tied and ﬁlled with 3 ml of KRB without (control) or with 1 nmol/l RELM-.
After 3 min of in situ incubation, 3 ml of 60 mmol/l glucose solution were
injected in the lumen to obtain a ﬁnal concentration of 30 mmol/l. After a
further 3 min, these loops were removed and opened along the mesenteric
border and the mucosa was scraped off on ice with a glass blade. Total cell
protein extracts and BBMs were prepared from the scrapings as previously
described (23), and enrichment was estimated by determination of alkaline
phosphatase activity (20-fold increase of activity in BBMs). Solubilized
proteins were resolved by electrophoresis on 10% SDS-PAGE gels and
transferred onto nitrocellulose membranes for immunoblot analysis. The
following rabbit antibodies were used at a 1:1,000 dilution: SGLT-1 (AB 1352;
Chemicon International, Temecula, CA), GLUT2, PKC II (sc-9117, sc-210;
Santa Cruz Biotechnology, Tebu-Bio, France), phospho-AMPK- (Thr172),
AMPK- (23A3), and phospho-PKC (pan (2531, 2603, 190D10; Cell Signaling
Technology, Ozyme, France). The intensity of the speciﬁc immunoreactive
bands was quantiﬁed using National Institutes of Health Image (Scion,
Frederick, MD).
Glucose uptake experiments. Uptake experiments were performed using
rat intestinal everted rings as previously described (24). Groups of eight
intestinal rings were incubated at 37°C for 15 min in oxygenized KRB buffer in
the absence (control) and the presence of RELM- (1 nmol/l) and cytochalasin
B as indicated. Then the rings were incubated for 2 min in an uptake solution
corresponding to a KRB buffer containing 30 mmol/l glucose and 0.1 Ci/ml of
the isotopic tracer D-[1-
14C] glucose. After adding the uptake solution, the
rings were washed in ice-cold KRB solution, and radioactivity incorporated in
the tissue was quantiﬁed by liquid scintillation. Data were not corrected for
extracellular substrate because RELM- was found not to affect paracellular
diffusion. Total protein from homogenized tissue with a Dounce homogenizer
was determined with bicinchoninic acid reagent from Pierce (Thermo Scien-
tiﬁc, Brebie `res, France). Results are expressed as micromoles glucose per
gram of tissue protein.
Chemicals. Recombinant murine RELM- was purchased from PeproTech
(Neuilly-sur-Seine, France). Antibody raised against RELM- was a gift from
Dr. Blagoy Blagoev (University of Southern Denmark). D-[1-
14C] Mannitol was
from GE Healthcare Amersham Biosciences (les Ulis, France), D-[1-
14C]
glucose was from Perkin Elmer (Boston, MA), and compound C from Merck
Sharp & Dohme-Chibret (Paris, France). All other chemical reagents were
purchased from Sigma (St. Louis, MO).
Statistical analysis. All results were expressed as means  SE. One-way
ANOVA with Turkey-Kramer multiple comparisons post hoc test was per-
formed using GraphPad Prism version 4.0 for Windows (GraphPad Software,
San Diego, CA). The level of signiﬁcance was set at P  0.05.
RESULTS
Effect of RELM- on glucose tolerance tests. Oral
administration of RELM- increased glycemia during
OGTT carried out in mice (Fig. 1A) and rats (Fig. 1B)a s
compared with control groups. The area under the curve
was signiﬁcantly (P  0.05) increased in mice when
RELM- was used at 1 nmol/l and the two doses used (0.1
and 1 nmol/l) were effective in rats (Fig. 1A and B, insets).
A similar 15% increase in blood glucose as compared with
control was observed in both mice and rats. These data
show that luminal administration of exogenous RELM- is
active in vivo as previously described (6).
Mucosal RELM- inhibits Na
-dependent glucose
transport. The route of glucose entry can involve active
Na
-dependent GLUT (SGLT-1) or diffusive transporter
GLUT2. We used the Ussing chamber to characterize the
effect of mucosal RELM- on rat intestinal active glucose
transport (SGLT-1). Rat jejunal mucosa mounted in the
chamber was allowed to reach a steady state (usually 40
min). Addition of 10 mmol/l glucose in the mucosal bath
induced a rise in Isc (maximum after 3 min) representing
an increase in SGLT-1 activity. Addition of RELM- to the
mucosal side 2 min before glucose challenge induced a
marked and dose-dependent inhibition of glucose-induced
Isc. As shown in Fig. 2A, addition of RELM- to the
mucosal side inhibited glucose transport by jejunal mu-
cosa in a concentration-dependent manner. Maximal inhi-
bition was achieved with 0.1 nmol/l RELM-. The
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(IC50) of glucose transport was 3 pmol/l. Further, an
overnight incubation of 0.1 nmol/l RELM- with an anti-
body raised against RELM- countered the inhibition of
glucose-induced Isc by RELM- as shown in Fig. 2B. Next,
we investigated if the observed inhibition by RELM- was
associated with an altered abundance of SGLT-1 in jejunal
BBMs. A typical immunoblot of SGLT-1 protein in BBMs
after glucose challenge in the presence or the absence of
RELM- is shown in Fig. 2C. The mean densitometry of
three separate blots shows that glucose increased the
amount of SGLT-1 protein in BBMs by 1.5-fold as com-
pared with control. This increase is reduced by half in the
presence of RELM-.
RELM- modulates jejunal glucose transport. We
isolated rat jejunum and performed in vitro studies of
transmural glucose transport to directly evaluate the effect
of RELM- on intestinal transport. As shown in Fig. 3A,
luminal glucose in jejunal loops signiﬁcantly increased net
mucosal to serosal glucose ﬂux. A dose-dependent effect
on glucose transport was observed with increasing glu-
cose concentrations 10, 30, and 100 mmol/l. Further,
RELM-, at 1 nmol/l, signiﬁcantly enhanced the jejunal
transport of 10, 30, and 100 mmol/l glucose but not that of
30 mmol/l mannitol. Thus, increased jejunal glucose trans-
port induced by RELM- is unlikely to have been caused
by changes in paracellular permeability. This is in line with
histological studies of the jejunum tissues used in these
experiments that did not show any visible mucosal dete-
rioration (data not shown). Further, experiments were
performed to identify if the effect of RELM- implicated
potential downstream kinases, PKC, and AMPK, which are
known as key effectors of intestinal glucose transport
(6,20,23,25). The AMPK inhibitor, compound C, and the
PKC inhibitor, chelerythrine, inhibited the 30 mmol/l glu-
cose-induced jejunal glucose transport as shown, respec-
tively, in Fig. 3B and C. The insets represent the area under
the curve of the 30-min glucose transport kinetics.
RELM- signiﬁcantly increased glucose transport by ap-
proximately twofold and this effect was blunted by com-
pound C and chelerythrine as shown, respectively, in Fig.
3B and C. These results indicate a likely involvement of
PKC and AMPK in the luminal effect of RELM- on glucose
uptake.
RELM- stimulates phosphorylation of AMPK and
translocation of PKC II. The above results prompted
us to assess by in situ experiments the cellular effects of
RELM- on AMPK and PKC. Jejunal segments were in-
jected with a KRB solution alone or containing 30 mmol/l
glucose in the absence and the presence of 1 nmol/l
RELM-. The mucosal scrapings of jejunum were exam-
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FIG. 1. OGTT in mice and rats. OGTT (1 g/kg) was performed in
overnight-fasted mice (A) or rats (B) with a 15% D-glucose solution
without (E, dotted lines) or with RELM- (F, 0.1 nmol/l; , 1 nmol/l).
Glucose concentration was determined in blood samples from the tail
and is expressed as milligram per deciliter over the time points
(minutes). Each point is the means  SE; n  6–10. *P < 0.05 vs.
control. Area under the curve (inset) is expressed in arbitrary units. In
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RELM-.
RELM-β [- log M]
11 10 9 8
0
20
40
60
80
100
G
l
u
c
o
s
e
-
i
n
d
u
c
e
d
 
I
s
c
 
(
%
)
12
0
0.5
1.0
1.5
D
e
n
s
i
t
o
m
e
t
r
y
 
(
a
r
b
i
t
a
r
y
 
u
n
i
t
s
)
-
--
+
+
Glucose
RELM-β
+
*
*
2
2
Δ
I
s
c
 
(
μ
A
/
c
m
 
 
)
0
10
20
30
+
+
Glucose
RELM-β
+
AB
-
+
+
- - +
*
B
C
* *
**
*
-
- +
- +
+
β-actin
SGLT-1
Glucose
RELM-β
A
FIG. 2. Effect of luminal RELM- on glucose-induced Isc. Rat jejunal
mucosa was mounted in Ussing chamber and the increase in Isc was
studied at steady state. Electrogenic (Na
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from rat jejunum loops incubated in situ with and without luminal
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to -actin and is representative of at least three separate experiments.
Each point of the Isc study represents the means  SE of four to eight
noncumulative values from ﬁve separate experiments. Signiﬁcant dif-
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2034 DIABETES, VOL. 58, SEPTEMBER 2009ined by Western blot analysis. The results indicated that
glucose as well as RELM- stimulated AMPK phosphory-
lation over control values as shown in Fig. 4A. The
corresponding mean densitometric analysis indicates that
RELM- induced a threefold increase in AMPK phosphor-
ylation. A further increase in the phosphorylation of AMPK
occurred when glucose and RELM- were added together.
Similarly, RELM- induced a threefold increase in PKC
phosphorylation in line with our data (6) in the mouse
colon (data not shown). This prompted us to study the
translocation of cytosolic PKC II of enterocytes to BBMs,
a mechanism that is associated with intestinal glucose
transport (20,23). We performed Western blot analysis to
determine the expression of PKC II in BBMs obtained
from intestinal segments that were incubated with glucose
(30 mmol/l) or RELM- (1 nmol/l) as described above. As
shown in Fig. 4B, RELM- or glucose induced, respec-
tively, 1.5- or 2-fold increase of PKC II at the BBMs as
compared with control values. A further increase (2.7-fold
compared with the control) of PKC II at the BBMs was
observed when RELM- and glucose were added together.
These results suggest that RELM- stimulates the phos-
phorylation of AMPK and PKC as well as an increased shift
of PKC II to the BBMs of rat jejunal tissue.
RELM- increases GLUT2 activity and its expression
at BBMs. We explored whether RELM- could enhance
the glucose-induced GLUT2 translocation to the apical
membrane of enterocytes. To this end, we measured
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FIG. 4. RELM- induces phosphorylation of AMPK and translocation of
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RESEARCH DESIGN AND METHODS. Representative immunoblots for phospho-
AMPK (A) in mucosal extracts and PKC II (B) in BBMs are shown.
The densitometry in A represents the amount of phosphorylated
kinases relative to total AMPK. The amount of PKC II in BBMs in B is
relative to total PKC. The data are representative of three separate
experiments. Signiﬁcantly different from control, *P < 0.05.
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of RELM- and without or with cytochalasin B, a compet-
itive inhibitor of GLUT2 (26). As shown in Fig. 5A,
cytochalasin B inhibited glucose uptake by 50% in agree-
ment with the implication of GLUT2 in glucose uptake
(27,28). RELM- enhanced glucose uptake by twofold and
this effect was also strongly inhibited by cytochalasin B.
Further, we performed Western blot analysis to determine
the expression of GLUT2 in BBMs obtained from intestinal
segments that had been incubated with RELM- under the
same conditions as above. We observed that glucose or
RELM- alone induced, respectively, a four- or threefold
increase in the amount of GLUT2 found in the brush-
border fraction, respectively (Fig. 5B). When glucose and
RELM- were added together, a further increase in the
amount of GLUT2 was observed (ﬁvefold as compared
with control). This suggests that RELM- enhanced glu-
cose uptake is a result of an increased insertion of GLUT2
into the BBMs.
DISCUSSION
In the present study, we show that RELM-, a resistin-like
molecule, can directly increase jejunal absorption of glu-
cose in the rat. Several lines of evidence suggest that
transepithelial transport of glucose in the small intestine
can be mediated by an active absorption through Na
/
glucose cotransporter (SGLT-1) as well as by a diffusive
component GLUT2 at the apical membrane (27). We found
that RELM- inhibited the activity of SGLT-1, whereas
enhancing the presence of GLUT2 at the BBM of entero-
cytes. Moreover, the increased jejunal glucose transport
induced by RELM- was inhibited by cytochalasin B in
agreement with a functional role of GLUT2. The underly-
ing molecular mechanism involves the activation of PKC
II and AMPK kinases as described for such reciprocal
regulation of glucose transporters (20).
The acute treatment of rat jejunum with RELM- had no
signiﬁcant effect on passive mannitol movement suggest-
ing that RELM- increases glucose transport by the use of
transporters. We found that mucosal RELM- inhibited the
activity and the translocation of cytosolic SGLT-1 to cell
membranes. This effect was blunted by an antibody raised
against RELM-. Other peptides such as leptin, angioten-
sin II, and CCK-8 have also been shown to inhibit SGLT-1
activity (14,16,28). We show that in contrast to CKK-8,
which seems to have no effect on GLUT2 (28), RELM- can
induce GLUT2 translocation. Indeed, in response to
RELM- the amount of GLUT2 was increased in the BBMs.
Similarly, a rapid insertion of GLUT2 to apical membrane
in response to another gut-peptide, GLP-2, has been re-
ported (29,30). Taken together, these ﬁndings suggest the
involvement of GLUT2 in RELM- stimulated glucose
uptake.
The mechanisms responsible for RELM- effect may
involve the activation of PKC (6) and AMPK (25) that have
been shown to regulate jejunal glucose transporters (20).
This is sustained by the report that luminal epidermal
growth factor increases jejunal glucose transport in rabbit
through PKC activity (31). We found that chelerythrine, an
inhibitor of PKC, blocked RELM- stimulation of glucose
uptake. The effect of RELM- is accompanied by an
increase in the amount of PKC II at the BBMs. The
activation of PKC has been shown to inhibit SGLT-1
mediated transport of hexoses (14,32). In oocytes express-
ing rat and rabbit SGLT-1, the activation of PKC decreases
the maximum rate of transport for both isoforms. This
change is accompanied by proportional change in the
number of SGLT-1 molecules at the plasma membrane,
indicating that PKC regulates endocytosis of the vesicles
containing the transporter (33). Further, SGLT-1 contains
a consensus site of PKC phosphorylation and thus PKC
phosphorylation of the transporter could control its activ-
ity (34). These data are in line with our results showing
that RELM- inhibits SGLT-1 activity and its translocation
to BBMs in rat small intestine.
The activation of AMPK has been shown to downregu-
late SGLT-1–dependent glucose transport but also to
enhance GLUT2 translocation to the apical membrane of
the jejunum (20). This effect of AMPK leads to an in-
creased glucose uptake in jejunum (20) as well as in
muscle (35). Interestingly, several hormones have been
shown to regulate AMPK in a strictly tissue-speciﬁc man-
ner (36). We demonstrate that the compound C blocked
RELM- stimulation of glucose transport in rat intestine
suggesting the involvement of AMPK. Humans and rodents
express two isoforms of the catalytic subunit (1, 2) that
form the heterotrimeric complex AMPK (, , and )
known to serve as a regulator of energy balance (37). We
showed that RELM- could increase the phosphorylation
of the conserved threonine residue (Thr-172) of 1i nt h e
jejunal mucosa that is crucial for the AMPK activity. As
evoked above, activated PKC decreases the number of
SGLT-1 transporters but can also activate the transloca-
tion of GLUT2 to BBMs as described elsewhere (23). Thus,
luminal RELM- can directly enhance glucose transport by
mustering GLUT2 at BBMs through PKC and AMPK
activation.
This inverse regulation of SGLT-1 and GLUT2 by luminal
RELM- may be important when enterocytes require en-
ergy as shown in stress-induced pathology (38). The
energy sensor molecule AMPK as well as PKC can increase
the GLUT2 energy-independent pathway to override that
of SGLT-1 that requires energy (20,32). In agreement with
this concept, the SGLT-1-mediated absorption of nutrients
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FIG. 5. Effect of RELM- on glucose uptake and GLUT2 trafﬁcking in
BBMs. A: Rat jejunal everted rings were incubated in oxygenized KRB
buffer without (control) or with 1 nmol/l RELM-. The presence of
cytochalasin B is indicated. The rings were incubated for 2 min in a
KRB buffer containing 30 mmol/l glucose and 0.1 Ci/ml of the isotopic
tracer D-[1-
14C] glucose). The radioactivity incorporated in the tissue
was determined by liquid scintillation. The amount of glucose incorpo-
rated is expressed as millimole per gram of tissue protein. B: Rat
jejunal loops were treated 6 min with a mucosal bath containing 30
mmol/l glucose with or without 1 nmol/l RELM- and BBMs were
prepared as described in RESEARCH DESIGN AND METHODS. A representative
Western blot analysis of the corresponding protein lysates with GLUT2
antibody is shown. Densitometric analysis of immunoblots indicates an
increase of GLUT2 in the presence of glucose or RELM-. The data are
expressed relative to -actin and is representative of at least three
separate experiments. Signiﬁcantly different from control, *P < 0.05.
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systemic (39) or intestinal inﬂammation (40). Further, to
meet the increased metabolic demand of inﬂamed tissue, it
has been shown that proinﬂammatory cytokines (interleu-
kin [IL]-8, IL-6, and IL-1) can increase jejunal absorption of
glucose without changes in BBM SGLT-1 content (41). An
increased expression of RELM- has been described in the
intestine during jejunal inﬂammation (19,42,43). The ex-
pression of RELM- is increased by several proinﬂamma-
tory cytokines and by lipopolysaccharide (9,21) and they
may act together to modulate intestinal glucose absorp-
tion. Thus, the enhanced glucose absorption by RELM- in
response to inﬂammatory stimulus may contribute to the
associated energy demand.
Obese and insulin-resistant rodent models that are char-
acterized by a low-grade inﬂammation are associated with
an increased expression of the gut-derived RELM- (8).
Expression of RELM- has been shown in rat (18) and
mice (19) proximal intestine and the peptide may act
locally in a paracrine manner or as a circulating hormone
linking the gut to the liver. When given by gavage, it is
possible that RELM- could be partly absorbed by the
small intestine to reach the blood as demonstrated for
leptin (44). In favor of a hormonal effect, the infusion of
intestinal RELM- in mice has been shown to promote a
marked increase in the rate of hepatic glucose production
(7). This was associated with a rapidly induced hepatic but
not peripheral insulin resistance. We observed that acute
RELM- administration in the intestinal lumen of rodents
resulted in an increased glycemia in OGTT. This could
result from the observed increased intestinal glucose
absorption and an acute hepatic insulin resistance (7).
This is in line with a local intestinal and distant action of
this gut peptide. As to whether RELM- may also counter-
act the described insulin inhibition of intestinal sugar
absorption remains to be established (45). There may be
different RELM- thresholds in insulin target tissues as
described for resistin (46). A better understanding of
RELM- action on different tissues could emerge if puta-
tive RELM- receptors were identiﬁed. In this context, the
effect of RELM- may even involve rapid neuronal activa-
tion because RELM family members RELM- (47) and
RELM- (4) can bind to neurons. Other than short-regula-
tion, RELM- can have a chronic effect as shown in
diet-induced metabolic disorders (25). Transgenic mice
over-expressing circulating RELM- exhibited signiﬁcant
hyperglycemia, hyperlipedemia when fed on high-fat diet.
In conclusion, our study shows that RELM- increases
intestinal glucose transport. Further studies may reveal if
this process in conjunction with an adverse nutritional and
inﬂammatory status, can participate in the onset of
diabetes.
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